Literature DB >> 18154867

Biophosphonate-related osteonecrosis of the jaws.

Salvatore L Ruggiero1, Sook-Bin Woo.   

Abstract

In 2003 and 2004, the first reports of patients who developed necrosis of the jawbones while taking biophosphonates appeared in literature; most patients were on this drug for treatment of cancer and some osteoporosis. Since then, more than 500 cases have been identified and the number of these cases continues to grow. This article reviews the action of bisphosphonates, the condition called bisphosphonate-associated osteonecrosis of the jaws, strategies to minimize occurrence, and treatment of this condition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18154867     DOI: 10.1016/j.cden.2007.09.002

Source DB:  PubMed          Journal:  Dent Clin North Am        ISSN: 0011-8532


  15 in total

1.  Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.

Authors:  Yanming Bi; Yamei Gao; Driss Ehirchiou; Chunzhang Cao; Takashi Kikuiri; Anh Le; Songtao Shi; Li Zhang
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

2.  Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw.

Authors:  M S Najm; D H Solomon; S-B Woo; N S Treister
Journal:  Oral Dis       Date:  2013-02-19       Impact factor: 3.511

3.  How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network.

Authors:  Cara B Gonzales; Veronica Young; Norma S Ketchum; Jamie Bone; Thomas W Oates; Rahma Mungia
Journal:  Gen Dent       Date:  2015 Mar-Apr

4.  Ozonated oil effect for prevention of medication-related osteonecrosis of the jaw (MRONJ) in rats undergoing zoledronic acid therapy.

Authors:  C G J Monteiro; E M Vieira; C Emerick; R S Azevedo; V A B Pascoal; N Homsi; R X Lins
Journal:  Clin Oral Investig       Date:  2021-04-25       Impact factor: 3.573

5.  The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report.

Authors:  Maria Del Pilar Rodríguez-Sánchez; Cristian Statkievicz; João Martins de Mello-Neto; Luan Felipe Toro; Ana Paula Farnezzi Bassi; Valdir Gouveia Garcia; Letícia Helena Theodoro; Edilson Ervolino
Journal:  J Lasers Med Sci       Date:  2020-01-18

6.  Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia.

Authors:  J W Hong; W Nam; I-H Cha; S-W Chung; H S Choi; K M Kim; K J Kim; Y Rhee; S-K Lim
Journal:  Osteoporos Int       Date:  2009-07-25       Impact factor: 4.507

7.  Oral lesions and lymphoproliferative disorders.

Authors:  P Castellarin; G Pozzato; G Tirelli; R Di Lenarda; M Biasotto
Journal:  J Oncol       Date:  2010-09-01       Impact factor: 4.375

8.  A Case of Pentastomiasis at the Left Maxilla Bone in a Patient with Thyroid Cancer.

Authors:  Eunae Sandra Cho; Seung Wook Jung; Hwi-Dong Jung; In Yong Lee; Tai-Soon Yong; Su Jin Jeong; Hyun Sil Kim
Journal:  Korean J Parasitol       Date:  2017-08-31       Impact factor: 1.341

9.  Nutritional Status in Patients with Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Johannes Laimer; Alexander Höller; Ute Pichler; Raphael Engel; Sabrina B Neururer; Alexander Egger; Andrea Griesmacher; Emanuel Bruckmoser
Journal:  Nutrients       Date:  2021-05-10       Impact factor: 5.717

10.  Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages.

Authors:  Daichi Muratsu; Daigo Yoshiga; Takaharu Taketomi; Tomohiro Onimura; Yoshihiro Seki; Akinobu Matsumoto; Seiji Nakamura
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.